In Vivo Anti-tumour Activity of FCE 23762, a Methoxymorpholinyl Derivative of Doxorubicin Active on Doxorubicin-resistant Tumour Cells

Overview

Journal Br J Cancer

Specialty Oncology

Date 1992 May 1

PMID 1586598

Citations 13

Authors

M Ripamonti

G Pezzoni

E Pesenti

A PASTORI

M Farao

A Bargiotti

A Suarato

F Spreafico

M Grandi

Affiliations

Soon will be listed here.

Abstract

FCE 23762 is a new doxorubicin derivative obtained by appending a methoxymorpholinyl group at position 3' of the sugar moiety. The compound is greater than 80 times more potent than doxorubicin, it is highly lipophilic, and presents equivalent anti-tumour activity when administered by i.p., i.v. or oral route. The pattern of anti-tumour activity of FCE 23762 differs from that of doxorubicin in maintaining anti-tumour activity against two P388 murine leukaemia sublines resistant to doxorubicin and, although at borderline levels of efficacy, against LoVo human colon adenocarcinoma resistant to doxorubicin. FCE 23762 exhibits remarkable efficacy against MX-1 human mammary carcinoma, with most treated mice being cured both after i.v. and oral treatment. Anti-tumour activity was also observed against L1210 murine leukaemia and two sublines resistant to cis-platinum and melphalan, M5076 murine reticulosarcoma, MTV murine mammary carcinoma and N592 human small cell lung cancer.

Citing Articles

Friend or Foe: Xenobiotic Activation of Nrf2 in Disease Control and Cardioprotection.

Hedrich W, Wang H Pharm Res. 2021; 38(2):213-241.

PMID: 33619640 DOI: 10.1007/s11095-021-02997-y.

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.

Fokkema E, Verweij J, Van Oosterom A, Uges D, Spinelli R, Valota O Br J Cancer. 2000; 82(4):767-71.

PMID: 10732743 PMC: 2374418. DOI: 10.1054/bjoc.1999.0996.

Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases.

Quintieri L, Rosato A, Amboldi N, Vizler C, Ballinari D, Zanovello P Br J Cancer. 1999; 79(7-8):1067-73.

PMID: 10098738 PMC: 2362260. DOI: 10.1038/sj.bjc.6690171.

Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.

Bakker M, Droz J, Hanauske A, Verweij J, Van Oosterom A, Groen H Br J Cancer. 1998; 77(1):139-46.

PMID: 9459159 PMC: 2151269. DOI: 10.1038/bjc.1998.22.

Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives.

Ripamonti M, Capolongo L, Melegaro G, Gornati C, Bargiotti A, Caruso M Invest New Drugs. 1996; 14(2):139-46.

PMID: 8913834 DOI: 10.1007/BF00210784.

References

Johnson R, Chitnis M, Embrey W, Gregory E . In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep. 1978; 62(10):1535-47. View

Izumoto S, Arita N, Hayakawa T, Ohnishi T, Taki T, Yamamoto H . Effect of MX2, a new morpholino anthracycline, against experimental brain tumors. Anticancer Res. 1990; 10(3):735-9. View

Facchetti I, Grandi M, Cucchi P, Geroni C, Penco S, Vigevani A . Influence of lipophilicity on cytotoxicity of anthracyclines in LoVo and LoVo/Dx human cell lines. Anticancer Drug Des. 1991; 6(5):385-97. View

Grandi M, Pezzoni G, Ballinari D, Capolongo L, Suarato A, Bargiotti A . Novel anthracycline analogs. Cancer Treat Rev. 1990; 17(2-3):133-8. DOI: 10.1016/0305-7372(90)90037-g. View

Barbieri B, Giuliani F, Bordoni T, CASAZZA A, Geroni C, Bellini O . Chemical and biological characterization of 4'-iodo-4'-deoxydoxorubicin. Cancer Res. 1987; 47(15):4001-6. View

Endicott J, Ling V . The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989; 58:137-71. DOI: 10.1146/annurev.bi.58.070189.001033. View

Kaye S . The multidrug resistance phenotype. Br J Cancer. 1988; 58(6):691-4. PMC: 2246872. DOI: 10.1038/bjc.1988.291. View

Rothenberg M, Ling V . Multidrug resistance: molecular biology and clinical relevance. J Natl Cancer Inst. 1989; 81(12):907-10. DOI: 10.1093/jnci/81.12.907. View

Goldstein L, Galski H, Fojo A, Willingham M, Lai S, Gazdar A . Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989; 81(2):116-24. DOI: 10.1093/jnci/81.2.116. View

10.

Beck W . The cell biology of multiple drug resistance. Biochem Pharmacol. 1987; 36(18):2879-87. DOI: 10.1016/0006-2952(87)90198-5. View

11.

Watanabe M, Komeshima N, Nakajima S, Tsuruo T . MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells. Cancer Res. 1988; 48(23):6653-7. View

12.

Grandi M, Geroni C, Giuliani F . Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin. Br J Cancer. 1986; 54(3):515-8. PMC: 2001636. DOI: 10.1038/bjc.1986.206. View

13.

Odaimi M, Andersson B, McCredie K, Beran M . Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia. Cancer Res. 1986; 46(7):3330-3. View

14.

Coley H, Twentyman P, Workman P . 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur J Cancer. 1990; 26(6):665-7. DOI: 10.1016/0277-5379(90)90112-7. View

15.

Beck W . Multidrug resistance and its circumvention. Eur J Cancer. 1990; 26(4):513-5. DOI: 10.1016/0277-5379(90)90028-r. View

16.

Di Marco A, Lenaz L, CASAZZA A, SCARPINATO B . Activity of adriamycin (NSC-123127) and daunomycin (NSC-82151) against mouse mammary carcinoma. Cancer Chemother Rep. 1972; 56(2):153-61. View